Wellness Goals · Attention and focus condition
ADHD in Adults: Attention, Evaluation and Care
Attention-deficit/hyperactivity disorder (ADHD) in adults · also called ADHD, adult ADHD, attention deficit disorder, ADD, TDAH, déficit de atención
ADHD in adults is a persistent pattern of inattention and/or hyperactivity and impulsivity that began in childhood and makes daily life harder at home, school or work. Here is how ADHD in adults is evaluated, what established care looks like (talking therapy, and medicine chosen with a specialist), and what research says about therapy, omega-3, exercise, sleep and other lifestyle changes. Evidence for natural options is mostly low or very low, and diagnosis and medicine decisions need a clinician.
General information, not medical advice. Last substantive update · Not medically reviewed. A named clinician has not signed off on this page. How this page is made
About ADHD in Adults: Attention, Evaluation and Care
ADHD in adults is a pattern of inattention, restlessness and impulsivity that began in childhood and affects daily life. Evaluation by a specialist uses history, interviews and rating scales. Established care combines medicine and talking therapy chosen with a clinician. For natural options, CBT has the strongest support; mindfulness, exercise and sleep programmes are low certainty, omega-3 is mixed, and herbs and diets are unproven.
What ADHD in adults is: attention, hyperactivity and impulsivity
NIMH says attention-deficit/hyperactivity disorder (ADHD) is marked by a persistent pattern of inattention and/or hyperactivity and impulsivity that makes it hard to function in at least two areas of life, such as home, school or work. It counts as a developmental disorder because symptoms must begin in childhood, but many adults have it. A 2021 global review estimated that 2.58% of adults have persistent ADHD that began in childhood, and 6.76% have ADHD symptoms whatever their age of onset. A World Federation of ADHD consensus statement, endorsed by 80 authors from 27 countries, gathers 208 findings supported by meta-analysis to counter misconceptions and stigma about the disorder.
The NHS lists being easily distracted or forgetful, finding it hard to organise time, losing things often, restlessness, talking a lot or interrupting, and making quick decisions without thinking. NIMH says many people show some of these behaviours some of the time; in ADHD they are more severe, frequent and persistent, appear in several situations and last at least 6 months. Inattentive symptoms often persist with age, while hyperactivity and impulsivity are more likely to decline.
Other conditions that look like or travel with ADHD
Trouble concentrating has many causes, including poor sleep, anxiety, depression and brain fog. The NHS says a GP may consider conditions such as autism, Tourette's or anxiety, and that people with ADHD often have other conditions too, such as depression, anxiety, addictions or a learning difficulty such as dyslexia. A large review found odds of anxiety disorders, depression, bipolar disorder and substance use disorders were about 4.5 to 8.7 times higher in adults with ADHD.
NIMH says sleep problems affect up to 70% of adults with ADHD. The NHS says ADHD is thought to be recognised less often in women than in men, perhaps because inattentive symptoms are harder to recognise; NIMH says sex differences in diagnosis begin to even out in adulthood.
How ADHD in adults is evaluated
NIMH says adults must have shown symptoms before age 12, so a diagnosis relies heavily on past reports of behaviour. A clinician may talk with people who know you well, look at school records, use clinical interviews and rating scales, test thinking skills such as memory and planning, and ask about mood and other medical conditions. Adults and teenagers over 16 must show five symptoms of inattention or hyperactivity and impulsivity rather than six.
The NHS says a GP will ask about your symptoms and may refer you to an ADHD specialist such as a psychiatrist; waiting times can be several months or years. NICE says only a specialist with training in ADHD should diagnose it, after a full clinical and psychosocial assessment. A 6-question self-report screener can flag likely cases (sensitivity 91.4%, specificity 96.0% in one study), but a screener is not a diagnosis. It is never too late to seek an evaluation.
Established care, in general terms
NIMH says the most common treatments are medication, usually stimulants, and psychotherapy such as behavioural or cognitive behavioural therapy, often in combination. The NHS adds lifestyle changes, workplace adjustments and talking therapies such as CBT or mindfulness, and says not everyone needs or wants medicine. NICE says medicine is offered when symptoms still cause significant impairment after environmental changes, and non-drug treatment is considered for adults who choose not to take medicine, cannot take it, or still have impairment on it.
A 2025 network meta-analysis of 113 trials in 14,887 adults found stimulants and atomoxetine reduced core symptoms in the short term on both self-rated and clinician-rated scales, but medicines did not improve quality of life and long-term evidence was thin. Medicine decisions belong with a specialist prescriber; never stop or change a prescribed medicine on your own.
The NHS says you can ask your workplace or place of study for reasonable adjustments, such as a quiet workspace, written as well as spoken instructions, or help planning tasks. A European consensus statement says effective evidence-based treatments exist but that ADHD is underdiagnosed and undertreated in many countries.
What therapy, omega-3, exercise and other lifestyle changes show
Of the non-drug approaches, CBT has the strongest support: a 2025 umbrella review rated the adult evidence as at least moderate certainty. Mindfulness, exercise, sleep-focused programmes and computerised brain training have low-certainty evidence. Omega-3 supplements have mixed results (no significant overall benefit, possible benefit in trials of 4 months or more). Herbs, caffeine with L-theanine, neurofeedback, diet changes and other complementary approaches have very low or insufficient evidence for adults.
NCCIH (2019) says research on complementary approaches is mixed or has not shown improvement. Natural does not mean safe or enough: these approaches may sit beside, never in place of, an assessment and the care your clinician advises.
At a glance
Traditional uses history, not proof
Studied for research
- Cognitive behavioural therapy (CBT) and other structured talking therapy, moderate certainty
- Mindfulness-based programmes, low certainty
- Exercise and physical activity, low certainty
- Sleep-focused approaches (CBT for insomnia, morning light), low certainty
- Omega-3 fatty acids (fish oil), mixed evidence
- Computerised brain training, low certainty
- Ginkgo, Bacopa and other herbal and focus supplements, very low certainty
- Caffeine and L-theanine, very low certainty
Main compounds
- Omega-3 fatty acids
- Bacopa monnieri
- Ginkgo biloba
- L-theanine
- Caffeine
Common forms
- Talking therapy and mindfulness programmes
- Exercise and sleep routines
- Oral supplements
Research links: Network meta-analysis of ADHD interventions in adults, Lancet Psychiatry 2025 · ADHD interventions umbrella review, BMJ 2025 · NIMH: ADHD in Adults · NHS: ADHD in adults · NICE guideline NG87 · NCCIH: ADHD at a Glance · Research Library · Genes & Biomarkers Library
What it is and its history
- Accepted scientific name
- Attention-deficit/hyperactivity disorder (ADHD) in adults
- Common names
- ADHD (English); Adult ADHD, attention deficit disorder, ADD (English); Trastorno por déficit de atención e hiperactividad (TDAH) (Spanish); TDAH en adultos (Spanish)
Traditional use and history history, not clinical proof
| Tradition or era | Documented use | Source |
|---|---|---|
| Modern guidance | Current guidance (NICE, 2018, with the NHS and NIMH) describes assessment by a specialist and treatment with medicine and/or talking therapy. No history older than current guidance was read for this page. | s-nice-ng87 |
Traditional use shows how it was used. It does not show that it works or is safe today.
What is inside, and how it may work
What it contains and how those compounds act in cells and animals. Laboratory and animal mechanisms are not proven effects in people.
Main compounds
| Compound | Family | Where it is concentrated | Activity studied | Level of evidence |
|---|---|---|---|---|
| Omega-3 fatty acids (EPA, DHA) | fatty acids | Studied as a fish-oil supplement. 11 | Human data | |
| Bacopa monnieri | herb | Reported to reduce inattention in small studies summarised in a review. 1 | Human data | |
| Ginkgo biloba | herb | Reported to reduce symptoms but less than a stimulant medicine in a review. 1 | Human data | |
| L-theanine | amino acid from tea | Studied with caffeine for attention and for sleep efficiency. 1 | Human data | |
| Caffeine | stimulant | No significant benefit alone in the review read. 1 | Human data |
Mechanisms, receptors and pathways
| Target or pathway | Gene or receptor | What was found | Level |
|---|---|---|---|
| What ADHD is | NIMH: inattention, hyperactivity and impulsivity that are more severe, frequent and persistent than usual, occur in several settings and last at least 6 months. 23 | Agency summary | |
| Causes | NHS: the cause is not always known; genetic differences are thought to play a part and ADHD often runs in families. Prematurity, epilepsy, brain injury and being autistic are linked. 21 | Agency summary |
Isolated compounds versus whole extracts
The studies read tested supplements, extracts and lifestyle programmes. No trial of a whole-food diet in adults with ADHD was read.
1 moderate certainty1 mixed findings4 low certainty2 very low certainty3 not enough evidence
What was looked at
The 11 benefits and uses checked for ADHD in Adults: Attention, Evaluation and Care, each with how strong the evidence is. Tap one to open it.
- Cognitive behavioural therapy (CBT) and other structured talking therapyModerate certainty
- Mindfulness-based programmesLow certainty
- Exercise and physical activityLow certainty
- Computerised brain trainingLow certainty
- Omega-3 fatty acids (fish oil)Mixed findings
- Ginkgo, Bacopa and other herbal and focus supplementsVery low certainty
- Caffeine and L-theanineVery low certainty
- Sleep-focused approaches (CBT for insomnia, morning light)Low certainty
- Neurofeedback and brain stimulationNot enough evidence
- Diet changes, balanced meals and elimination dietsNot enough evidence
- Acupuncture, yoga, meditation, chiropractic and homeopathyNot enough evidence
Lab markers tracked in the studies
ADHD core symptom severityExecutive function (planning and self-control tests)Insomnia Severity Index
What is ADHD in Adults: Attention, Evaluation and Care good for?
The natural and lifestyle approaches that have been studied for ADHD in adults, and how strong the human evidence is for each. These describe what studies found, not advice to use them. They do not replace the evaluation and care described in the About tab.
Benefits, one by one
Each card is a research question, not a promise. Tap a goal to filter. Open a card to see the studies, doses and limits.
Cognitive behavioural therapy (CBT) and other structured talking therapy
Moderate certaintyA 2025 umbrella review rated the evidence that CBT reduces ADHD symptoms in adults as at least moderate certainty, with a medium effect. A 2026 meta-analysis of 14 trials found benefits for core symptoms, executive function, low mood and anxiety. A 2025 network meta-analysis found CBT beat placebo on clinician-rated scales only. NICE advises a structured, supportive psychological intervention focused on ADHD for adults who choose not to take medicine or for whom medicine is not enough.
5 studiesIndividual or group CBT, sometimes alongside medicine, as reported in…
Studies, doses and limits
What the trials found
Umbrella review of 47 meta-analytic reports (2025); network meta-analysis of 113 trials in 14,887 adults (2025); meta-analysis of 14 CBT trials (2026); network meta-analysis of 37 non-drug trials (2025).
Results
CBT beat controls in several reviews. In the network meta-analysis the gain showed on clinician-rated but not self-rated scales. Group formats did better for core symptoms; individual CBT did better for mood and anxiety. Quality of life and self-evaluation did not change.
Effect sizes as reported
Core symptoms SMD -0.45 across 14 trials; clinician-rated SMD -0.76 (CI -1.26 to -0.26) in the network meta-analysis. A fourth review reports much larger numbers but rates its own confidence very low or low.
Why this rating
Moderate, the umbrella review's own grading for adults: medium effect sizes, but non-drug trials cannot be fully blinded, rater results differ, and the network meta-analysis rated confidence lower. No high-certainty long-term evidence exists.
Form and dose studied
Individual or group CBT, sometimes alongside medicine, as reported in the trials. No amounts or schedules are advised here.
Who was studied
Adults with a formal ADHD diagnosis; trials were mostly short.
Limits
Self-rated and clinician-rated scales disagree; outcomes beyond symptoms were mixed; long-term data are thin.
Why researchers looked
Therapy teaches planning, time management and ways to cope with distraction and emotions, which are the daily problems adults with ADHD describe.
Proposed mechanism Hypothesis
Skills-based: therapy is thought to build organisation and coping habits. This was not tested directly in the reviews read.
A proposed mechanism does not show that the effect happens in people.
CBT is generally a low-risk option; a clinician or therapist with ADHD experience should guide it. It does not replace medical assessment.
Mindfulness-based programmes
Low certaintyA 2025 meta-analysis of 10 controlled studies found mindfulness programmes improved self-rated and observer-rated ADHD symptoms and daily functioning in adults, but not mood or mindfulness skills. The umbrella review gave mindfulness in adults a large effect but low-certainty evidence, and the network meta-analysis found it better than placebo on clinician-rated scales only.
3 studiesGroup or individual mindfulness courses as reported. No amounts or sc…
Studies, doses and limits
What the trials found
Meta-analysis of 10 controlled studies (2025, searched to 2023); umbrella review; network meta-analysis.
Results
Symptoms and functioning improved in the pooled studies; mood and mindfulness skills did not.
Effect sizes as reported
Self-rated symptoms SMD 0.48 (CI 0.19 to 0.76); observer-rated 0.32 (0.09 to 0.56); functioning 0.56 (0.22 to 0.90).
Why this rating
Low, because the umbrella review rated the certainty low, only ten small studies (some not randomised) were pooled, and the network meta-analysis found no self-rated gain.
Form and dose studied
Group or individual mindfulness courses as reported. No amounts or schedules are advised here.
Who was studied
Adults with ADHD, mostly in small trials.
Limits
Few studies, some without randomisation, short follow-up.
Why researchers looked
Attention training is a core part of mindfulness, so it is a natural fit for people who struggle to hold attention.
Proposed mechanism Hypothesis
Proposed: practising present-moment attention may strengthen attention control. Not tested directly in the reviews read.
A proposed mechanism does not show that the effect happens in people.
Generally gentle; some people find sitting still hard when restless. Ask a clinician if you have trauma or severe anxiety.
Exercise and physical activity
Low certaintyTwo 2025 to 2026 meta-analyses of small randomised trials found a single session of exercise improved inhibitory control and gave a small improvement in core symptoms in adults with ADHD; results for longer programmes were mixed. The NHS and NICE encourage regular physical activity for adults with ADHD.
4 studiesSingle sessions and programmes of several exercise types as reported.…
Studies, doses and limits
What the trials found
Meta-analysis of 8 articles (373 adults, 2025); meta-analysis of 14 studies with 8 pooled (2026).
Results
A single session helped a lab test of stopping an automatic response (inhibitory control) and slightly helped symptom scores. Pilates, Tai Chi and cycling were among the types with effects; yoga showed none.
Effect sizes as reported
Single session: inhibitory control g 0.55 (CI 0.32 to 0.79); core symptoms g 0.23 (CI 0.03 to 0.43).
Why this rating
Low: few, small, short trials; the symptom benefit is small and its interval barely excludes zero; benefits of long programmes are mixed.
Form and dose studied
Single sessions and programmes of several exercise types as reported. No amounts or schedules are advised here.
Who was studied
Adults with ADHD, mostly small trials.
Limits
Lab-task outcomes more than everyday life; very wide intervals; programme results inconsistent.
Why researchers looked
Exercise is linked to better mood, sleep and attention in general, and NHS says anxiety and depression can make ADHD worse.
Proposed mechanism Hypothesis
Proposed: exercise may affect brain chemicals involved in attention. This was not tested directly in the reviews read.
A proposed mechanism does not show that the effect happens in people.
Choose activity suited to your health; ask a clinician if you have heart or joint problems.
Computerised brain training
Low certaintyA 2023 meta-analysis of 9 randomised trials found computerised cognitive training gave a small gain in overall thinking test scores in adults with ADHD, but no significant change in ADHD symptoms, executive function, speed or working memory.
2 studiesComputer training programmes as reported; products are not named here…
Studies, doses and limits
What the trials found
Meta-analysis of 9 randomised trials (2023).
Results
A small overall cognitive gain; no symptom benefit.
Effect sizes as reported
Overall cognition g 0.235 (CI 0.002 to 0.467).
Why this rating
Low: few trials, small effect that barely excludes zero, and no benefit on symptoms. Ostinelli 2025 also found cognitive remediation better than placebo on clinician-rated scales only.
Form and dose studied
Computer training programmes as reported; products are not named here. No amounts or schedules are advised here.
Who was studied
Adults with ADHD.
Limits
Small trials with similar designs; unclear whether gains carry into daily life.
Why researchers looked
Many programmes are marketed to improve focus and memory.
Proposed mechanism Hypothesis
Proposed: practising tasks strengthens the brain skills they use. Not supported for symptoms in the review read.
A proposed mechanism does not show that the effect happens in people.
Little risk apart from time and cost; no product is recommended here.
Omega-3 fatty acids (fish oil)
Mixed findingsA 2023 meta-analysis of 22 trials (1,789 people) found omega-3 supplements did not significantly improve ADHD core symptoms overall, but trials lasting at least 4 months showed a significant benefit. NCCIH (2019) says it is unclear whether omega-3 helps ADHD. The abstract does not separate adults from children.
2 studiesDifferent omega-3 products and ratios were pooled; a higher EPA dose …
Studies, doses and limits
What the trials found
Meta-analysis of 22 randomised trials (2023); NCCIH summary (2019).
Results
No significant overall gain; a gain in trials of at least 4 months.
Effect sizes as reported
Overall SMD -0.16 (CI -0.34 to 0.01); 4 months or longer SMD -0.35 (CI -0.61 to -0.09).
Why this rating
Mixed: the overall result missed significance, a subgroup was positive, subgroups were small, and the abstract does not say how many participants were adults.
Form and dose studied
Different omega-3 products and ratios were pooled; a higher EPA dose or ratio did not help. No amounts or schedules are advised here.
Who was studied
People with ADHD of mixed ages in small trials.
Limits
Moderate heterogeneity and no data on what people ate.
Why researchers looked
Omega-3 fats are part of brain cell membranes and are a common supplement for attention.
Proposed mechanism Hypothesis
Proposed: omega-3 fats affect brain signalling and inflammation. Not tested directly in the review.
A proposed mechanism does not show that the effect happens in people.
Fish oil can thin the blood slightly and cause fishy burps or stomach upset; ask a doctor or pharmacist, especially before surgery or if you take blood thinners.
Ginkgo, Bacopa and other herbal and focus supplements
Very low certaintyA 2025 systematic review reported that Bacopa monnieri and Ginkgo biloba reduced ADHD symptoms in small studies, with ginkgo less effective than a stimulant medicine. NCCIH (2019) says research on St. John's wort, French maritime pine bark extract and ginkgo is limited and has not shown that they improve ADHD symptoms.
2 studiesHerbal extracts as reported; products are not named here. No amounts …
Studies, doses and limits
What the trials found
Systematic review of supplement studies (2025, mixed ages); NCCIH summary (2019).
Results
Reported symptom reductions in small studies, but an agency review of the same area found no proof of benefit.
Effect sizes as reported
No pooled numbers in the abstract.
Why this rating
Very low: small studies, mixed ages, no numbers in the abstract, and NCCIH says benefit has not been shown.
Form and dose studied
Herbal extracts as reported; products are not named here. No amounts or schedules are advised here.
Who was studied
Mixed ages; the abstract does not separate adults.
Limits
No adult-only trial results could be read.
Why researchers looked
Plant extracts are widely marketed for focus.
Proposed mechanism Hypothesis
Proposed: effects on blood flow and brain signalling. Not tested directly in the reviews read.
A proposed mechanism does not show that the effect happens in people.
St. John's wort can weaken many medicines, including important ones. Ask a doctor or pharmacist before any herb.
Caffeine and L-theanine
Very low certaintyThe 2025 supplement review found caffeine alone showed no significant benefit for ADHD symptoms; caffeine combined with L-theanine may enhance attention, and L-theanine improved sleep efficiency but not other sleep measures.
2 studiesCaffeine and L-theanine alone or combined as reported. No amounts or …
Studies, doses and limits
What the trials found
Systematic review (2025); abstract only.
Results
No clear benefit of caffeine alone; a possible attention gain with L-theanine.
Effect sizes as reported
No numbers in the abstract.
Why this rating
Very low: a narrative summary of small studies without numbers.
Form and dose studied
Caffeine and L-theanine alone or combined as reported. No amounts or schedules are advised here.
Who was studied
Mixed ages.
Limits
The abstract gives no numbers or ages for these studies.
Why researchers looked
Many adults with ADHD use coffee or tea to focus.
Proposed mechanism Hypothesis
Proposed: caffeine is a stimulant and L-theanine from tea is calming. Not tested directly here.
A proposed mechanism does not show that the effect happens in people.
The NHS advises avoiding caffeine, sugar and alcohol close to bedtime; caffeine can worsen sleep and anxiety.
Sleep-focused approaches (CBT for insomnia, morning light)
Low certaintySleep problems affect up to 70% of adults with ADHD (NIMH). A 2021 review found three small studies of morning light therapy with a significant effect on sleep, and preliminary evidence for melatonin, behavioural therapy and weighted blankets. A 2019 pilot of 19 adults found insomnia scores fell after a group CBT-based sleep programme; a 2025 review found short-term benefit from CBT for insomnia in autism and/or ADHD that was often not kept at follow-up.
4 studiesGroup CBT-I based programmes and morning light as reported. No amount…
Studies, doses and limits
What the trials found
Narrative review of 6 studies (2021); pilot of 19 adults (2019); systematic review of 8 studies (2025).
Results
Insomnia severity improved in the pilot; light therapy helped in three small studies.
Effect sizes as reported
Insomnia Severity Index fell 4.5 points after treatment and 6.8 at 3 months in the 19-adult pilot.
Why this rating
Low: small studies, one without a control group, results often not maintained.
Form and dose studied
Group CBT-I based programmes and morning light as reported. No amounts or schedules are advised here.
Who was studied
Adults with ADHD and sleep problems.
Limits
Very small samples, self-reported outcomes, mixed conditions in the 2025 review.
Why researchers looked
Poor sleep worsens attention, and ADHD can disturb sleep.
Proposed mechanism Hypothesis
Proposed: ADHD may involve a shifted body clock. Not tested directly here.
A proposed mechanism does not show that the effect happens in people.
Sleep problems can have other causes such as sleep apnea; see a clinician if they are persistent.
Neurofeedback and brain stimulation
Not enough evidenceA 2025 meta-analysis of 18 studies in adults found no technique (neurofeedback, tDCS or rTMS) reached significance when pooled, and called neurofeedback studies low quality. NCCIH (2019) says neurofeedback results are mixed. The network meta-analysis found tDCS better than placebo on clinician-rated scales only.
3 studiesNeurofeedback sessions or brain stimulation as reported; these are cl…
Studies, doses and limits
What the trials found
Meta-analysis of 18 studies (2025); network meta-analysis (2025); NCCIH.
Results
No significant pooled effect.
Effect sizes as reported
No significant pooled effect.
Why this rating
Insufficient: pooled results were not significant, study quality low, and ratings disagree between raters.
Form and dose studied
Neurofeedback sessions or brain stimulation as reported; these are clinic procedures. No amounts or schedules are advised here.
Who was studied
Adults with ADHD in small studies.
Limits
Small samples and varied methods.
Why researchers looked
These are non-drug approaches that train or stimulate the brain.
Proposed mechanism Hypothesis
Proposed: changing brain activity patterns. Not demonstrated in the pooled data.
A proposed mechanism does not show that the effect happens in people.
Brain stimulation is a clinical procedure; discuss with a specialist.
Diet changes, balanced meals and elimination diets
Not enough evidenceNICE says healthcare professionals should stress the value of a balanced diet, good nutrition and regular exercise for adults with ADHD, and the NHS suggests a balanced diet and regular mealtimes. No adult trial of a specific diet or elimination diet was read.
2 studiesGeneral eating pattern, as the NHS describes it. No amounts or schedu…
Studies, doses and limits
What the trials found
Guideline and agency advice only; no adult diet trial read.
Results
General healthy-eating advice, not a treatment.
Effect sizes as reported
No numbers.
Why this rating
Insufficient: guidelines give general advice but no adult trial of a specific diet was read.
Form and dose studied
General eating pattern, as the NHS describes it. No amounts or schedules are advised here.
Who was studied
Adults with ADHD.
Limits
No adult diet trial was found among the sources read.
Why researchers looked
People often ask whether sugar, additives or food sensitivities affect ADHD.
Proposed mechanism Hypothesis
No mechanism was tested in the sources read.
A proposed mechanism does not show that the effect happens in people.
Restrictive diets can leave nutrition gaps; ask a doctor or dietitian first.
Acupuncture, yoga, meditation, chiropractic and homeopathy
Not enough evidenceNCCIH (2019) says the limited research on acupuncture, chiropractic, meditation and yoga for ADHD is not conclusive and there is no evidence that homeopathic products help. The 2025 umbrella review rated acupuncture in children and adolescents as large but low certainty; no adult result is given. The exercise review found no clear effect of yoga on inhibitory control in adults.
3 studiesPractices named in the sources; no routine or schedule is advised her…
Studies, doses and limits
What the trials found
NCCIH summary (2019); umbrella review (2025); exercise meta-analysis (2025).
Results
Not conclusive.
Effect sizes as reported
No numbers for adults.
Why this rating
Insufficient for adults: few adult trials and an agency summary calls the research inconclusive.
Form and dose studied
Practices named in the sources; no routine or schedule is advised here.
Who was studied
Mostly children or mixed ages.
Limits
No adult trial of acupuncture, chiropractic or homeopathy was read.
Why researchers looked
These approaches are popular alongside or instead of standard care.
Proposed mechanism Hypothesis
No mechanism was tested in the sources read.
A proposed mechanism does not show that the effect happens in people.
Tell any practitioner about your medicines; manipulation and needling need a trained practitioner.
Connections to the rest of health
How ADHD in Adults: Attention, Evaluation and Care connects to the rest of our health knowledge graph. Every link says what kind of connection it is. A safety link (for example to the liver) is a warning, not a benefit. A study that merely mentions a topic never creates a benefit link.
Explore every connection: goals, body systems, organs, symptoms, genes
A. Wellness goals
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Focus Memory | Moderate certainty | Cognitive behavioural therapy (CBT) and other structured talking therapy: A 2025 umbrella review rated the evidence that CBT reduces ADHD symptoms in adults as at least moderate certainty, with a medium effect. A 2026 meta-analysis of 14 trials found benefits for core symptoms, executive function, low mood and anxiety. A 2025 network meta-analysis found CBT beat placebo on clinician-rated scales only. NICE advises a structured, supportive psychological intervention focused on ADHD for adults who choose not to take medicine or for whom medicine is not enough. Mindfulness-based programmes: A 2025 meta-analysis of 10 controlled studies found mindfulness programmes improved self-rated and observer-rated ADHD symptoms and daily functioning in adults, but not mood or mindfulness skills. The umbrella review gave mindfulness in adults a large effect but low-certainty evidence, and the network meta-analysis found it better than placebo on clinician-rated scales only. | 6 13 12 18 22 9 17 19 21 4 11 20 1 2 | |
| Stress | Low certainty | Mindfulness-based programmes: A 2025 meta-analysis of 10 controlled studies found mindfulness programmes improved self-rated and observer-rated ADHD symptoms and daily functioning in adults, but not mood or mindfulness skills. The umbrella review gave mindfulness in adults a large effect but low-certainty evidence, and the network meta-analysis found it better than placebo on clinician-rated scales only. | 9 6 13 | |
| Energy | Low certainty | Exercise and physical activity: Two 2025 to 2026 meta-analyses of small randomised trials found a single session of exercise improved inhibitory control and gave a small improvement in core symptoms in adults with ADHD; results for longer programmes were mixed. The NHS and NICE encourage regular physical activity for adults with ADHD. | 17 19 21 22 | |
| Sleep | Very low certainty | Caffeine and L-theanine: The 2025 supplement review found caffeine alone showed no significant benefit for ADHD symptoms; caffeine combined with L-theanine may enhance attention, and L-theanine improved sleep efficiency but not other sleep measures. | 1 21 | |
| Sleep | Low certainty | Sleep-focused approaches (CBT for insomnia, morning light): Sleep problems affect up to 70% of adults with ADHD (NIMH). A 2021 review found three small studies of morning light therapy with a significant effect on sleep, and preliminary evidence for melatonin, behavioural therapy and weighted blankets. A 2019 pilot of 19 adults found insomnia scores fell after a group CBT-based sleep programme; a 2025 review found short-term benefit from CBT for insomnia in autism and/or ADHD that was often not kept at follow-up. | 15 8 3 23 | |
| Focus Memory | Low certainty | Sleep-focused approaches (CBT for insomnia, morning light): Sleep problems affect up to 70% of adults with ADHD (NIMH). A 2021 review found three small studies of morning light therapy with a significant effect on sleep, and preliminary evidence for melatonin, behavioural therapy and weighted blankets. A 2019 pilot of 19 adults found insomnia scores fell after a group CBT-based sleep programme; a 2025 review found short-term benefit from CBT for insomnia in autism and/or ADHD that was often not kept at follow-up. | 15 8 3 23 | |
| Focus Memory | Not enough evidence | Diet changes, balanced meals and elimination diets: NICE says healthcare professionals should stress the value of a balanced diet, good nutrition and regular exercise for adults with ADHD, and the NHS suggests a balanced diet and regular mealtimes. No adult trial of a specific diet or elimination diet was read. Acupuncture, yoga, meditation, chiropractic and homeopathy: NCCIH (2019) says the limited research on acupuncture, chiropractic, meditation and yoga for ADHD is not conclusive and there is no evidence that homeopathic products help. The 2025 umbrella review rated acupuncture in children and adolescents as large but low certainty; no adult result is given. The exercise review found no clear effect of yoga on inhibitory control in adults. | 22 21 20 6 19 | |
| Gut Digestive | Not enough evidence | Diet changes, balanced meals and elimination diets: NICE says healthcare professionals should stress the value of a balanced diet, good nutrition and regular exercise for adults with ADHD, and the NHS suggests a balanced diet and regular mealtimes. No adult trial of a specific diet or elimination diet was read. | 22 21 |
B. Body systems
E. Health conditions
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Insomnia | Health agency guidance | NIMH says sleep problems affect up to 70% of adults with ADHD. Preparation or compound: Sleep problems |
23 | |
| Anxiety disorders | Meta analysis | Anxiety disorders had pooled odds of 5.0 in adults with ADHD compared with those without. Preparation or compound: Comorbidity |
7 |
I. Biomarkers
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| ADHD core symptom severity | Biological association | Moderate certainty | Measured in trials: Lower scores mean fewer symptoms; several approaches lowered clinician-rated scores more than self-rated scores. A lab change is not the same as a health benefit. | 13 6 |
| Executive function (planning and self-control tests) | Biological association | Low certainty | Measured in trials: Higher scores mean better control; improved after exercise and CBT in pooled studies. A lab change is not the same as a health benefit. | 17 12 |
| Insomnia Severity Index | Biological association | Low certainty | Measured in trials: Lower is better; fell 4.5 points after a group CBT-based sleep programme (19 adults). A lab change is not the same as a health benefit. | 8 |
L. Active compounds
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Omega-3 fatty acids (EPA, DHA) | Biological association | Human | Studied as a fish-oil supplement. | 11 |
| Bacopa monnieri | Biological association | Human | Reported to reduce inattention in small studies summarised in a review. | 1 |
| Ginkgo biloba | Biological association | Human | Reported to reduce symptoms but less than a stimulant medicine in a review. | 1 |
| L-theanine | Biological association | Human | Studied with caffeine for attention and for sleep efficiency. | 1 |
| Caffeine | Biological association | Human | No significant benefit alone in the review read. | 1 |
Each connection is stored with the ingredient, the connected record, the kind of connection, the evidence status, the supporting studies, the preparation or compound involved, and a review date (last reviewed October 31, 2026).
Evidence at a glance: what the research found for 11 outcomes
Each outcome below is one thing researchers measured. Certainty is how far the evidence can be trusted, not how well it works. The full studies are on the next tab.
The evidence
The research centre for ADHD in Adults: Attention, Evaluation and Care. Every record here was checked against PubMed or the publisher's page; we never list a study we have not verified.
Evidence by outcome
Bars show how many studies we found for each outcome, not how well it works. People are added up across trials only (reviews are not added, to avoid double counting).
How we rate evidence
High certainty
Several well-run trials or reviews agree; further research is unlikely to change the picture much.
Moderate certainty
Good trials point the same way, but some doubt remains.
Low certainty
Small, short or inconsistent trials. The finding could change with better research.
Very low certainty
Very little or very weak human data. Treat as a possibility only.
Mixed findings
Trials or reviews disagree with each other.
Not enough evidence
Not enough human research to say either way.
Evidence against
Good research found no benefit, or found harm.
We take the reviewers' own risk-of-bias and GRADE statements where they exist, and otherwise judge from study size, design, consistency, directness and whether a product matches what is sold. Many publications do not make evidence high. Method note: We searched PubMed, read the abstract of every review and guideline cited, and read the NIMH, NHS, NICE and NCCIH pages in full. Certainty ratings are the compiler's own reading unless a review gives its own grade.
Study library: every study we checked 24
| Study | Design | People | Product, dose, length | Result |
|---|---|---|---|---|
| Al Shahab 2025 Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review Nutrients · PMID 40362791 · DOI |
Systematic review |
Randomised, open-label and cross-sectional studies of supplements in people with ADHD, with or without stimulant medicine (the abstract does not give numbers or separate adults from children) | L-theanine, caffeine, Ginkgo biloba and Bacopa monnieri · vs Various |
Caffeine alone showed no significant benefit; with L-theanine it may help attention. L-theanine improved sleep efficiency only. Bacopa and ginkgo were reported to reduce symptoms, ginkgo less than methylphenidate. The authors say supplements cannot replace stimulant medicine. No pooled numbers in the abstract. Methods, limits and fundingOutcomes: ADHD symptoms (inattention, hyperactivity), memory, sleep Limitations: Only two databases, mixed study designs, mixed ages and no numbers in the abstract; these are the authors' summaries of small studies. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Courrèges 2025 Comparative efficacy of neurofeedback, tDCS, and TMS: The future of therapy for adults with ADHD. A systematic review and meta-analysis J Affect Disord · PMID 40505983 · DOI |
Systematic review meta analysis |
18 studies of neurofeedback and brain stimulation (tDCS, rTMS) in adults with ADHD | Neurofeedback, transcranial direct current stimulation, repetitive magnetic stimulation · vs Sham or other controls |
Meta-analysis did not reach significance for any technique. Neurofeedback studies were of low quality. No significant pooled effect for any technique. Methods, limits and fundingOutcomes: ADHD symptoms Limitations: Small studies and variable methods; neurofeedback evidence is of low quality. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Cullen 2025 Effectiveness of Cognitive Behavioural Therapy for Insomnia (CBT-I) in Individuals With Neurodevelopmental Conditions: A Systematic Review J Sleep Res · PMID 40180888 · DOI |
Systematic review |
598 8 studies (598 people, 3 in adults) of CBT for insomnia in autism and/or ADHD |
Cognitive behavioural therapy for insomnia (CBT-I) components · vs Various |
Two randomised trials and six before-after studies suggested short-term benefit in autism and/or ADHD, but findings were inconsistent and mostly not kept at follow-up. No pooled numbers. Methods, limits and fundingOutcomes: Insomnia and condition-related symptoms Limitations: Quality was moderate; small samples, no blinding, mixed methods; includes autism and children as well as adults with ADHD. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Elbe 2023 Computerized cognitive interventions for adults with ADHD: A systematic review and meta-analysis Neuropsychology · PMID 36892894 · DOI |
Systematic review meta analysis |
9 randomised trials of computerised cognitive training in adults with ADHD | Computerised cognitive training (brain-training programmes) · vs Control conditions |
A small improvement in overall cognitive functioning, but no significant improvement in symptoms, executive function, speed or working memory. Overall cognition Hedges g 0.235 (CI 0.002 to 0.467, P = 0.048). Methods, limits and fundingOutcomes: Overall cognitive functioning; ADHD symptom severity; executive function, speed, working memory Limitations: Small, similar trials; the overall effect barely excludes zero; symptoms did not improve. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Faraone 2021 The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder Neurosci Biobehav Rev · PMID 33549739 · DOI |
Consensus statement |
Large studies and meta-analyses of ADHD across the lifespan; statement endorsed by 80 authors from 27 countries | Not an intervention study |
The statement collects findings that are supported by meta-analysis, to counter misconceptions and stigma. 208 statements. Methods, limits and fundingOutcomes: 208 evidence-based statements about the nature, course, outcomes, causes and treatment of ADHD Limitations: The abstract does not list the statements, so none are quoted here. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Gosling 2025 Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making BMJ · PMID 41297970 · DOI |
Umbrella review |
Umbrella review of 47 meta-analytic reports covering 221 comparisons across the lifespan; adult results drawn from reviews of randomised trials | Medicines and non-drug interventions · vs Passive control (no treatment or placebo) |
In adults, CBT, atomoxetine and methylphenidate (and amphetamines in high-quality trials) had at least moderate-certainty evidence of benefit on symptoms, with medium effects. Mindfulness in adults had a large effect but low-certainty evidence. No intervention had high-certainty long-term evidence. Medicines had worse tolerability than placebo in adults (tolerability risk ratio, where below 1 is worse than placebo: atomoxetine 0.45, CI 0.35 to 0.58). Effects for CBT and mindfulness in adults were described as medium and large respectively. Methods, limits and fundingOutcomes: ADHD symptom severity by rater and time point; acceptability and tolerability; daily functioning; quality of life Limitations: Depends on the quality of the meta-analyses it re-analysed; mixes child and adult findings in one paper; most trials were short. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Hartman 2023 Anxiety, mood, and substance use disorders in adult men and women with and without attention-deficit/hyperactivity disorder: A substantive and methodological overview Neurosci Biobehav Rev · PMID 37149075 · DOI |
Meta analysis overview |
15097562 Large population studies (surveys, claims data, registries) with 550,748 adults with ADHD and 14,546,814 without |
Not an intervention study · vs Adults without ADHD |
All four groups of conditions were far more common in adults with ADHD, in both men and women. Pooled odds ratios: anxiety disorders 5.0 (CI 3.29 to 7.46), depression 4.5 (2.44 to 8.34), bipolar disorder 8.7 (5.47 to 13.89), substance use disorders 4.6 (2.72 to 7.80). Methods, limits and fundingOutcomes: Anxiety, depression, bipolar disorder and substance use disorders Limitations: Observational, so it shows association not cause; too little data to say how this changes across adult life. Funding and conflicts: Research support from US NIH and non-US government sources is listed in the record; no conflict statement read. Read: abstract |
| Jernelöv 2019 Effects and clinical feasibility of a behavioral treatment for sleep problems in adult attention deficit hyperactivity disorder (ADHD): a pragmatic within-group pilot evaluation BMC Psychiatry · PMID 31340804 · DOI |
Pilot before after |
19 19 adults (average age 37; 68% women) with ADHD and sleep problems at a specialist clinic; 79% used stimulant medicine |
Group sleep treatment based on CBT for insomnia (10 weekly 90-minute sessions) |
Insomnia severity improved after treatment and further at 3 months. Improvement of 4.5 points after treatment (CI 2.06 to 6.99) and 6.8 points at 3 months (CI 4.71 to 8.91) on the 0 to 28 scale. Methods, limits and fundingOutcomes: Insomnia Severity Index (0 to 28) after treatment and at 3 months Limitations: Only 19 people, no control group, self-reported outcomes only, registered after the study. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Kim 2025 Mindfulness-based interventions for adults with ADHD: A systematic review and meta-analysis Medicine (Baltimore) · PMID 40958241 · DOI |
Systematic review meta analysis |
10 controlled studies (randomisation not required) of mindfulness-based programmes in adults with ADHD | Mindfulness-based interventions · vs Control group |
Mindfulness programmes improved self-rated and observer-rated ADHD symptoms and daily functioning. They did not significantly change mood or mindfulness skills. Self-reported symptoms SMD 0.48 (CI 0.19 to 0.76); observer-rated 0.32 (0.09 to 0.56); functioning 0.56 (0.22 to 0.90) (the paper reports improvement as positive). Methods, limits and fundingOutcomes: Self-reported and observer-rated ADHD symptoms, mood, mindfulness skills, daily functioning Limitations: Only 10 studies, some not randomised, searched to 2023; the authors call for longer high-quality trials. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Kooij 2019 Updated European Consensus Statement on diagnosis and treatment of adult ADHD Eur Psychiatry · PMID 30453134 · DOI |
Consensus statement |
63 experts from European and other countries | Not an intervention study |
ADHD often presents as a lifelong impairing condition that is underdiagnosed and undertreated in many European countries. Screening and diagnostic instruments exist, as do effective evidence-based treatments. No numbers; a consensus statement. Methods, limits and fundingOutcomes: Clinical picture, diagnosis and treatment of adult ADHD Limitations: Expert consensus, not a trial; the abstract gives no recommendations in detail. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Liu 2023 Omega-3 Polyunsaturated Fatty Acids for Core Symptoms of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials J Clin Psychiatry · PMID 37656283 · DOI |
Meta-analysis |
1789 22 randomised trials of omega-3 supplements against placebo in people with ADHD (the abstract does not separate adults from children) |
Omega-3 fatty acid supplements (EPA, DHA and combinations) · vs Placebo |
Overall no significant improvement in core symptoms. In trials lasting at least 4 months there was a significant benefit. Neither a high EPA dose nor a high EPA:DHA ratio improved symptoms. Overall SMD -0.16 (CI -0.34 to 0.01, P = .07); trials of 4 months or longer SMD -0.35 (CI -0.61 to -0.09, P = .007). Methods, limits and fundingOutcomes: ADHD core symptoms; subgroups by duration, EPA dose and EPA:DHA ratio Limitations: Moderate heterogeneity, small subgroups, no information on what participants ate, and the abstract does not say how many were adults. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Liu 2026 A meta-analysis of the intervention effect of cognitive behavioral therapy on adult ADHD J Affect Disord · PMID 41483880 · DOI |
Meta-analysis |
14 randomised trials of CBT in adults with ADHD (949 records screened) | Cognitive behavioural therapy (individual, group, with or without medicine) · vs Control conditions |
CBT helped core symptoms, executive function, low mood and anxiety or stress. It did not significantly change quality of life or self-evaluation. Group formats did better for core symptoms; individual CBT did better for emotional outcomes. Core symptoms SMD -0.45 (P < 0.00001); depressed mood -0.23; anxiety or stress -0.24; executive function -0.43; quality of life 0.12 (not significant). Methods, limits and fundingOutcomes: Core symptoms, depressed mood, anxiety or stress, executive function, quality of life, self-evaluation Limitations: Abstract gives no confidence intervals or risk-of-bias grades; subgroup findings are exploratory. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Ostinelli 2025 Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis Lancet Psychiatry · PMID 39701638 · DOI |
Systematic review network meta analysis |
14887 113 randomised trials of adults (18 and over) with a formal ADHD diagnosis; 63 trials of medicines, 28 of psychological therapies, 10 of brain stimulation or neurofeedback |
Medicines, psychological therapies, cognitive training and brain stimulation · vs Placebo or other controls |
Stimulants and atomoxetine beat placebo on both self-rated and clinician-rated scales. CBT, cognitive remediation, mindfulness, psychoeducation and tDCS beat placebo only on clinician-rated scales. Medicines did not improve quality of life, and long-term evidence was thin. Clinician-rated: stimulants SMD -0.61 (CI -0.71 to -0.51), atomoxetine -0.51 (-0.64 to -0.37), CBT -0.76 (-1.26 to -0.26), mindfulness -0.79 (-1.29 to -0.29), psychoeducation -0.77 (-1.35 to -0.18). Confidence ranged from very low to moderate. Methods, limits and fundingOutcomes: ADHD core symptoms at about 12 weeks on self-rated and clinician-rated scales; dropout for any reason Limitations: Confidence in the results was very low to moderate; non-drug results differed between self-raters and clinicians (who may know the treatment given); few trials of each non-drug therapy. Funding and conflicts: UK National Institute for Health and Care Research. Abstract states people with lived experience took part. Read: abstract |
| Song 2021 The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis J Glob Health · PMID 33692893 · DOI |
Systematic review meta analysis |
Population-based studies of the general adult population from 2000 onward | Not an intervention study |
Prevalence fell with age. After adjusting to the 2020 world population, persistent adult ADHD (with childhood onset) was 2.58% and symptomatic adult ADHD (any onset) 6.76%. About 139.84 million adults with persistent ADHD and 366.33 million with symptomatic ADHD worldwide in 2020 (the authors' estimate). Methods, limits and fundingOutcomes: Prevalence of adult ADHD Limitations: Studies used different definitions; the authors call for a well-defined diagnostic strategy. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Surman 2021 Managing Sleep in Adults with ADHD: From Science to Pragmatic Approaches Brain Sci · PMID 34679425 · DOI |
Narrative review |
Six prospective studies of sleep treatments in adults with ADHD | Morning light therapy, melatonin, behavioural therapy, weighted blankets · vs Various |
Three studies of morning light therapy found a significant effect on sleep. Melatonin, behavioural therapy and weighted blankets had preliminary support only. Many sleep treatments are unstudied in adult ADHD. No pooled numbers in the abstract. Methods, limits and fundingOutcomes: Sleep quality and sleep problems Limitations: A narrative review of very few, mostly small studies; no pooled analysis. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Ustun 2017 The World Health Organization Adult Attention-Deficit/Hyperactivity Disorder Self-Report Screening Scale for DSM-5 JAMA Psychiatry · PMID 28384801 · DOI |
Diagnostic accuracy study |
637 637 adults in general-population and clinic samples, tested with a research diagnostic interview |
Six-question screening scale (ASRS for DSM-5) · vs Semistructured diagnostic interview |
A 6-question self-report screener picked out adults who met the DSM-5 interview criteria well in the general-population data. Sensitivity 91.4%, specificity 96.0%, AUC 0.94, positive predictive value 67.3% (population-weighted data). Methods, limits and fundingOutcomes: Sensitivity, specificity and positive predictive value of the screener Limitations: A screener is not a diagnosis; about a third of those it flags in the general population would not meet criteria. Funding and conflicts: Research support from US NIH and non-US government sources is listed in the record; no conflict statement read. Read: abstract |
| Xu 2026 The effects of acute and chronic exercise on executive functions and core symptoms in adults with ADHD: A systematic review and meta-analysis Psychol Sport Exerc · PMID 41638541 · DOI |
Systematic review meta analysis |
14 studies in the review, 8 in the meta-analysis, of adults with ADHD (parallel-group and crossover trials) | Acute (single session) and chronic (programme) exercise · vs Non-exercise control |
A single exercise session had a moderate positive effect on inhibitory control and a small effect on core symptoms. For longer exercise programmes the results were mixed. Acute exercise: inhibitory control Hedges g 0.55 (CI 0.32 to 0.79); core symptoms g 0.23 (CI 0.03 to 0.43). Methods, limits and fundingOutcomes: Executive functions (thinking skills) and core ADHD symptoms Limitations: Few studies; the symptom effect is small and the interval touches zero closely; long-term programmes were not pooled. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Yang 2025 Short-term and long-term effect of non-pharmacotherapy for adults with ADHD: a systematic review and network meta-analysis Front Psychiatry · PMID 39958157 · DOI |
Systematic review network meta analysis |
2289 37 randomised trials of 10 non-drug therapies in adults with ADHD |
Non-drug therapies (CBT, mindfulness-based cognitive therapy and others) · vs Control conditions |
CBT ranked best for core symptoms, depression and anxiety, short and long term. Mindfulness-based cognitive therapy was suggested for people without other conditions. CBT core symptoms SMD -4.43 short term and -3.61 long term (CIs given in the abstract). These effect sizes are far larger than other reviews report and are not repeated as a headline. Methods, limits and fundingOutcomes: Core symptoms, depression and anxiety, short and long term Limitations: Risk of bias was high in 48.6% of trials; confidence in the evidence was very low or low for most treatments. The authors urge caution. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| Yang 2025 The impact of physical activity on inhibitory control of adult ADHD: a systematic review and meta-analysis J Glob Health · PMID 40084538 · DOI |
Systematic review meta analysis |
373 8 articles (14 studies, 373 adults with ADHD) of randomised trials of physical activity |
Physical activity (acute single sessions and longer programmes; Pilates, Tai Chi, cycling, vibration training, yoga) · vs Non-exercise control |
Both a single session and a longer programme improved inhibitory control. Pilates, Tai Chi, cycling and vibration training showed effects; yoga did not. Acute exercise SMD -0.65 (CI -1.10 to -0.20); chronic exercise SMD -1.77 (CI -2.84 to -0.69). The abstract prints a few intervals that do not match their P values, so type-level numbers are not repeated here. Methods, limits and fundingOutcomes: Inhibitory control (a task-based measure of stopping an automatic response) Limitations: Few small trials, very wide intervals, a lab-task outcome rather than everyday symptoms; the abstract itself lists inconsistent numbers for some exercise types. Funding and conflicts: No funding or conflict statement in the record read. Read: abstract |
| s-nccih-adhd NCCIH: Attention-Deficit Hyperactivity Disorder at a Glance (last updated May 2019) · Source |
Health agency n/a |
Methods, limits and fundingRead: full-text | ||
| s-nhs-adhd NHS: ADHD in adults (page last reviewed 19 March 2025) · Source |
Health agency n/a |
Methods, limits and fundingRead: full-text | ||
| s-nice-ng87 NICE guideline NG87: ADHD, diagnosis and management (published 2018, updated 2019, last reviewed July 2026) · Source |
Health agency n/a |
Methods, limits and fundingRead: full-text | ||
| s-nimh-adhd NIMH: ADHD in Adults, 4 Things to Know (2024) · Source |
Health agency n/a |
Methods, limits and fundingRead: full-text | ||
| s-nimh-help NIMH: Find Help (immediate help and the 988 Lifeline) · Source |
Health agency n/a |
Methods, limits and fundingRead: full-text |
What we do not know yet
- No long-term (a year or more) trial of any non-drug approach in adults was read with high-certainty results.
- The 2025 umbrella review and network meta-analysis disagree in places because they use different methods; neither is the final word.
- No adult-only randomised trial of omega-3 or herbal supplements could be read from the abstracts.
- No trial of a specific diet or elimination diet in adults with ADHD was read.
- No ADHD-specific pregnancy or breastfeeding advice for the natural options was found in the sources read.
How new research is added
New studies are found by a saved PubMed search and placed in a review queue before the page changes.
Lab markers
What changed in blood or saliva tests during trials. A changed number is not the same as feeling or being healthier, and we give no "normal ranges".
Other 3
ADHD core symptom severity
Lower scores mean fewer symptoms; several approaches lowered clinician-rated scores more than self-rated scores in trials
Scores on rating scales of inattention, hyperactivity and impulsivity, filled in by the person or by a clinician.
Moderate certaintyResults and what it means
Why it was measured
The main outcome in ADHD trials.
Statistical vs. clinical meaning
Self-rated and clinician-rated scores can disagree, so the rater matters.
| Study | Result | People | Product |
|---|---|---|---|
| 13 | Stimulants and atomoxetine lowered both self-rated and clinician-rated scores; CBT, mindfulness, psychoeducation and tDCS lowered clinician-rated scores only. | 14,887 adults in 113 trials | Medicines, therapies and stimulation |
Executive function (planning and self-control tests)
Higher scores mean better control; improved after exercise and CBT in pooled studies in trials
Task-based tests of planning, stopping an automatic response and working memory.
Low certaintyResults and what it means
Why it was measured
Executive function problems are part of daily life in ADHD.
Statistical vs. clinical meaning
Lab tasks may not reflect daily function.
| Study | Result | People | Product |
|---|---|---|---|
| 17 | Inhibitory control improved after a single exercise session (g 0.55). | Adults with ADHD in 8 pooled studies | Acute exercise |
Insomnia Severity Index
Lower is better; fell 4.5 points after a group CBT-based sleep programme (19 adults) in trials
A 0 to 28 questionnaire; higher means more severe insomnia.
Low certaintyResults and what it means
Safety
What studies and official sources say about side effects, medicines and who should check first. Each point shows what kind of evidence it comes from.
Main points to know 6
- Trouble focusing has many causes: see a clinician for an evaluation. The NHS says a GP will ask about symptoms and consider other conditions such as autism, Tourette's or anxiety, and may refer you to an ADHD specialist. NICE says adults should be referred to a mental health specialist trained in ADHD when symptoms began in childhood, are not explained by another condition and cause moderate or severe impairment. This page cannot diagnose you. Health agency guidance 21 22
- Never stop or change a prescribed medicine on your own. The NHS says ADHD medicines must be started and monitored by an ADHD specialist. Medicine choices, side-effect checks and stopping belong with the prescriber. In adults, the 2025 reviews found stimulants and atomoxetine had worse tolerability than placebo, so keep follow-up appointments. Health agency guidance and systematic review 21 6 13
- Mood, anxiety and suicide risk need attention. The NHS says people with ADHD may be more likely to have anxiety and depression and are at higher risk of suicide. A large review found odds of anxiety, depression, bipolar disorder and substance use disorders were roughly 4.5 to 8.7 times higher in adults with ADHD. Tell a clinician if your mood is low, you feel on edge, or you use alcohol or drugs to cope. Health agency guidance and meta analysis 21 7
- Herbs and supplements can have side effects and interact with medicines. NCCIH says dietary supplements may have side effects and interact with some medications, and that St. John's wort can weaken the effects of many medicines, including crucially important ones. Talk to your health care provider before using any complementary approach. Health agency guidance 20
- Sleep problems are common and worth treating. NIMH says sleep problems affect up to 70% of adults with ADHD. The NHS suggests a regular bedtime, a quiet dark bedroom and avoiding screens, caffeine, sugar and alcohol close to bedtime. Persistent sleep trouble deserves a clinician's review. Health agency guidance 23 21
- Driving. In the UK, the NHS says you must tell the DVLA if your driving is affected by your ADHD or your ADHD medicine, or both. Check the rules where you live. Health agency guidance 21
Side effects 3
| Effect | How often | Severity and recovery | Evidence |
|---|---|---|---|
| Stopping treatment because of side effects (ADHD medicines, for discussion with a prescriber) | In adults, the umbrella review reported tolerability risk ratios (below 1 is worse than placebo, based on dropouts due to side effects) of 0.45 for atomoxetine, 0.50 for methylphenidate and 0.40 for amphetamines. | Not graded in the abstract | Umbrella review of randomised trials 6 |
| Lower acceptability of some medicines than placebo | The network meta-analysis found atomoxetine (OR 1.43) and guanfacine (OR 3.70) were less acceptable than placebo; stimulants were similar to placebo. | Not graded in the abstract | Network meta analysis of randomised trials 13 |
| Side effects of supplements and herbs | NCCIH gives no rate; the abstracts of the supplement reviews give no adverse-event numbers. | Not graded | Health agency guidance 20 1 |
Medicines and supplements 2
| With | Why it matters | Importance | Evidence | What to do |
|---|---|---|---|---|
| St. John's wort and prescription medicines prescription | NCCIH says St. John's wort can weaken the effects of many medicines, including crucially important ones. | Can matter for any medicine you take, not only ADHD medicines. | Health agency guidance Moderate certainty 20 | Ask a doctor or pharmacist before using it. |
| Herbal and focus supplements with ADHD medicines supplement | No study found. | No interaction study of ginkgo, Bacopa, L-theanine, caffeine or omega-3 with ADHD medicines was read. Absence of a study is not proof of safety. | Absence of evidence Not enough evidence 1 | Tell your prescriber and pharmacist about every supplement, herb and energy drink you use. |
Who should check first 4
| Situation | Advice | Evidence |
|---|---|---|
| Pregnancy, trying to conceive or breastfeeding | No source read gave ADHD-specific pregnancy advice for the natural options. Ask a doctor or pharmacist before using any supplement or medicine. | No source read |
| Depression, bipolar disorder, anxiety, substance use or other conditions alongside ADHD | These are far more common in adults with ADHD and can change which treatment is suitable. A specialist should assess them together. | Meta analysis and agency guidance 7 21 |
| New attention or memory changes that began in later life | NIMH says ADHD symptoms must begin in childhood. New or worsening attention or memory problems later in life have many possible causes, so see a doctor rather than self-diagnosing. | Health agency guidance 23 |
| People who take other medicines or have heart, blood-pressure or liver conditions | Do not add supplements or herbs without asking the prescriber. NICE advises regular review, including weight, for adults on ADHD medicine. | Health agency guidance 22 |
Overdose, product quality and regulators
| Body | Action | Date |
|---|---|---|
| NHS (England) (United Kingdom) | Says ADHD can be managed with lifestyle changes, workplace adjustments, medicines or talking therapies such as CBT or mindfulness; ADHD medicines must be started and monitored by an ADHD specialist; notes higher risk of suicide; lists exercise, sleep and a balanced diet. source | 2025-03-19 |
| NICE (United Kingdom) | Guideline NG87 recommends referral for specialist assessment, a structured supportive psychological intervention for adults who choose not to take medicine, balanced diet and regular exercise, and ongoing review for those on medicine. source | 2026-07-23 |
| NIMH (US) (United States) | Describes ADHD in adults, diagnosis relying on past reports of behaviour, and medicine and psychotherapy as the most common treatments. source | 2024 |
| NCCIH (US) (United States) | Says research on complementary approaches for ADHD is mixed or has not shown improvement; supplements may have side effects and interact with medicines. source | 2019-05 |
When to get medical help
- Thoughts of ending your life: tell someone now. In the US, NIMH says to call or text 988 or call 911; elsewhere use your local emergency number or crisis line, or go to the nearest emergency department.
- Feeling unable to keep yourself safe, or severe low mood: seek urgent help from a doctor or local emergency services.
- Using alcohol or drugs to cope with ADHD symptoms: speak to a doctor, because substance use is much more common in adults with ADHD.
- Side effects, mood changes or sleeplessness after starting or changing a medicine or supplement: contact your prescriber or pharmacist rather than stopping on your own.
Stop using the product and contact a clinician or emergency service. In the US, Poison Control is 1-800-222-1222.
General information only, not medical advice. Ask a clinician or pharmacist before use, especially with medicines, in pregnancy or with a health condition. See the Natural Remedy Safety guide.
Frequently asked questions
What is ADHD in adults?
NIMH describes ADHD as a persistent pattern of inattention and/or hyperactivity and impulsivity that makes it hard to function in at least two areas of life. It is a developmental disorder because symptoms start in childhood, but many adults have it.
Can adults have ADHD if it was never diagnosed in childhood?
Yes. NIMH says teachers and parents may not have recognised it, or a milder form may have been managed until adult demands increased, especially at work. Symptoms must still have started before age 12, so diagnosis relies on past reports.
How is ADHD diagnosed in adults?
Can an online ADHD test diagnose me?
No. A 6-question screener flagged DSM-5 cases well in one study (sensitivity 91.4%, specificity 96.0%), but about a third of those flagged in the general population did not meet criteria on interview, so it only suggests who should be assessed.
What treatments are used for ADHD in adults?
Does CBT help adults with ADHD?
Do omega-3 supplements help adult ADHD?
Does exercise help ADHD in adults?
Are herbs or "focus" supplements proven for ADHD?
Is trouble concentrating always ADHD?
No. Poor sleep, anxiety, depression and other conditions also affect focus. The NHS says a GP will consider other conditions that could cause your symptoms before referring you for assessment.
Why are sleep problems common with ADHD?
Explore by health goal
Editorial transparency
- Written by
- AlternativeMed editorial team. Research compiled with AI assistance, then checked against PubMed records.
- Medical review
- None. This page has not been reviewed by a physician or pharmacist.
- First published
- 2026-10-31
- Last substantive update
- 2026-10-31
- How we research
- We searched PubMed, read the abstract of every review and guideline cited, and read the NIMH, NHS, NICE and NCCIH pages in full. Certainty ratings are the compiler's own reading unless a review gives its own grade.
- How we rate evidence
- See "How we rate evidence" in the Evidence tab.
- Independence
- No product is promoted on this page. No affiliate links are shown.
Sources 24
Each source was opened and checked. Where we read only the abstract, it says so. The small numbers in the text point here.
- Al Shahab S, Al Balushi R, Qambar A et al.. Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review. Nutrients. 2025. PMID 40362791. DOI 10.3390/nu17091482. (abstract)
- Courrèges M, Hoareau M, Levenes C et al.. Comparative efficacy of neurofeedback, tDCS, and TMS: The future of therapy for adults with ADHD. A systematic review and meta-analysis. J Affect Disord. 2025. PMID 40505983. DOI 10.1016/j.jad.2025.119585. (abstract)
- Cullen M, McCrory S, Hooman G et al.. Effectiveness of Cognitive Behavioural Therapy for Insomnia (CBT-I) in Individuals With Neurodevelopmental Conditions: A Systematic Review. J Sleep Res. 2025. PMID 40180888. DOI 10.1111/jsr.70058. (abstract)
- Elbe P, Bäcklund C, Vega-Mendoza M et al.. Computerized cognitive interventions for adults with ADHD: A systematic review and meta-analysis. Neuropsychology. 2023. PMID 36892894. DOI 10.1037/neu0000890. (abstract)
- Faraone SV, Banaschewski T, Coghill D et al.. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021. PMID 33549739. DOI 10.1016/j.neubiorev.2021.01.022. (abstract)
- Gosling CJ, Garcia-Argibay M, De Prisco M et al.. Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making. BMJ. 2025. PMID 41297970. DOI 10.1136/bmj-2025-085875. (abstract)
- Hartman CA, Larsson H, Vos M et al.. Anxiety, mood, and substance use disorders in adult men and women with and without attention-deficit/hyperactivity disorder: A substantive and methodological overview. Neurosci Biobehav Rev. 2023. PMID 37149075. DOI 10.1016/j.neubiorev.2023.105209. (abstract)
- Jernelöv S, Larsson Y, Llenas M et al.. Effects and clinical feasibility of a behavioral treatment for sleep problems in adult attention deficit hyperactivity disorder (ADHD): a pragmatic within-group pilot evaluation. BMC Psychiatry. 2019. PMID 31340804. DOI 10.1186/s12888-019-2216-2. (abstract)
- Kim HH, Jung NH. Mindfulness-based interventions for adults with ADHD: A systematic review and meta-analysis. Medicine (Baltimore). 2025. PMID 40958241. DOI 10.1097/MD.0000000000044308. (abstract)
- Kooij JJS, Bijlenga D, Salerno L et al.. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019. PMID 30453134. DOI 10.1016/j.eurpsy.2018.11.001. (abstract)
- Liu TH, Wu JY, Huang PY et al.. Omega-3 Polyunsaturated Fatty Acids for Core Symptoms of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials. J Clin Psychiatry. 2023. PMID 37656283. DOI 10.4088/JCP.22r14772. (abstract)
- Liu Y, Zhu F, Yu Y et al.. A meta-analysis of the intervention effect of cognitive behavioral therapy on adult ADHD. J Affect Disord. 2026. PMID 41483880. DOI 10.1016/j.jad.2025.121107. (abstract)
- Ostinelli EG, Schulze M, Zangani C et al.. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. Lancet Psychiatry. 2025. PMID 39701638. DOI 10.1016/S2215-0366(24)00360-2. (abstract)
- Song P, Zha M, Yang Q et al.. The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. J Glob Health. 2021. PMID 33692893. DOI 10.7189/jogh.11.04009. (abstract)
- Surman CBH, Walsh DM. Managing Sleep in Adults with ADHD: From Science to Pragmatic Approaches. Brain Sci. 2021. PMID 34679425. DOI 10.3390/brainsci11101361. (abstract)
- Ustun B, Adler LA, Rudin C et al.. The World Health Organization Adult Attention-Deficit/Hyperactivity Disorder Self-Report Screening Scale for DSM-5. JAMA Psychiatry. 2017. PMID 28384801. DOI 10.1001/jamapsychiatry.2017.0298. (abstract)
- Xu S, Zhao C, Hu L. The effects of acute and chronic exercise on executive functions and core symptoms in adults with ADHD: A systematic review and meta-analysis. Psychol Sport Exerc. 2026. PMID 41638541. DOI 10.1016/j.psychsport.2026.103088. (abstract)
- Yang X, Zhang L, Yu J et al.. Short-term and long-term effect of non-pharmacotherapy for adults with ADHD: a systematic review and network meta-analysis. Front Psychiatry. 2025. PMID 39958157. DOI 10.3389/fpsyt.2025.1516878. (abstract)
- Yang Y, Wu CH, Sun L et al.. The impact of physical activity on inhibitory control of adult ADHD: a systematic review and meta-analysis. J Glob Health. 2025. PMID 40084538. DOI 10.7189/jogh.15.04025. (abstract)
- . NCCIH: Attention-Deficit Hyperactivity Disorder at a Glance (last updated May 2019). . . (full-text)
- . NHS: ADHD in adults (page last reviewed 19 March 2025). . . (full-text)
- . NICE guideline NG87: ADHD, diagnosis and management (published 2018, updated 2019, last reviewed July 2026). . . (full-text)
- . NIMH: ADHD in Adults, 4 Things to Know (2024). . . (full-text)
- . NIMH: Find Help (immediate help and the 988 Lifeline). . . (full-text)
